Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 2,842,427 |
|
|||||
| News | - | ||||||
| Day High | 18.8999 | Low High |
|||||
| Day Low | 15.34 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 2.95 | 19.31% | 18.2425 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.38 | 15.34 | 18.8999 | 18.44 | 15.29 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 23,119 | 2,842,427 | US$ 17.11 | US$ 48,646,458 | - | 4.22 - 18.8999 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:57:19 | 10 | US$ 18.25 | USD |
Nurix Therapeutics (NRIX) Options Flow Summary
Nurix Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 901.61M | 48.89M | - | 76.99M | -143.95M | -2.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nurix Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.15 | 18.8999 | 14.44 | 15.87 | 1,340,712 | 3.09 | 20.41% |
| 1 Month | 15.68 | 18.8999 | 14.44 | 15.81 | 907,777 | 2.56 | 16.34% |
| 3 Months | 13.81 | 18.8999 | 11.90 | 15.09 | 1,092,892 | 4.43 | 32.10% |
| 6 Months | 9.08 | 18.8999 | 7.65 | 13.15 | 944,968 | 9.16 | 100.91% |
| 1 Year | 10.84 | 18.8999 | 4.22 | 11.26 | 711,642 | 7.40 | 68.29% |
| 3 Years | 28.73 | 37.425 | 4.22 | 14.57 | 509,828 | -10.49 | -36.50% |
| 5 Years | 20.25 | 52.38 | 4.22 | 17.42 | 464,554 | -2.01 | -9.91% |
Nurix Therapeutics Description
| Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
